Article Text

Download PDFPDF

331 A novel small molecule inhibitor of CBL-B shows potent antitumor activity in combination with Pmel-1 adoptive cell transfer in an aggressive mouse melanoma model
  1. Marilena Gallotta,
  2. Jose Gomez Romo,
  3. Serena Ranucci,
  4. Austin Tenn-McClellan,
  5. Frederick Cohen,
  6. Gwenn Hansen,
  7. Arthur Sands,
  8. Ryan Rountree and
  9. Cristiana Guiducci
  1. Nurix Therapeutics, San Francisco, CA, USA


Background Adoptive cell transfer (ACT) involving engineered T cells (CAR-T) or autologous tumor-specific lymphocytes (TIL) induces effective antitumor response in advanced cancer patients. However, tumors frequently relapse after an initial response due to suboptimal T-cell activation and expansion within the tumor microenvironment. Moreover, current ACT treatment paradigms require application of high dose bolus infusions of IL-2 which are associated with acute toxicities restricting the use of ACT in the clinic. The E3 ubiquitin ligase Casitas B-lineage lymphoma B (CBL-B) is highly expressed in T cells, where it functions as an intracellular checkpoint that constrains T-cell activation following T cell receptor (TCR) engagement, therefore limiting T cell-mediated antitumor responses.

Methods We have developed two highly potent small molecule inhibitors of CBL-B to increase T-cell antitumor function both in vitro (NX-0255) and in vivo (NX-1607).

Results We previously reported that addition of NX-0255 during in vitro treatment of tumor-specific T cells increases the frequency and absolute numbers of less exhausted CD8+ memory T cells, profoundly improving their functionality and ability to control tumor growth following ACT in tumor-bearing mice. Here, we hypothesized that CBL-B inhibition could reduce the requirement for IL-2 bolus and utilized the Pmel-1 ACT/B16 melanoma tumor model to compare the antitumor effect of post infusion in vivo treatments with NX-1607 to high dose IL-2. C57BL/6 mice were implanted with B16-OVA and received Pmel-1 CD8+ T cells activated in vitro using anti-CD3 stimulation and NX-0255 combined with IL-2, followed by systemic treatment with either IL-2 (IP, 150000 IU for three days, BID) or oral NX-1607 (30 mg/kg, QD). We found that ACT supported by in vivo treatment with NX-1607 increased the antitumor activity of Pmel-1 cells when compared to ACT alone. Importantly, the increased antitumor activity of NX-1607-supported ACT was comparable to IL-2. Spectral cytometry analysis performed at 7 and 14 days after ACT showed that following NX-1607, a larger fraction of circulating Pmel-1 cells had a central-memory phenotype and expressed high levels of Granzyme B. Interestingly, both in vivo treatments induced increased 4-1BB/CD137 expression that significantly correlates with antitumor response.

Conclusions These findings demonstrated that oral dosing of NX-1607 in combination with ACT can support the functionality of transferred cells providing a robust antitumor response in the aggressive B16-OVA model. Treatment with NX-1607 induces a more favorable T cell phenotype compared to IL-2 treatment and is well tolerated. The observed antitumor effects of NX-1607 support its potential use in combination with cell-based therapeutics.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.